UPCOMING SESSIONS in ET
Tue, Jun 2, 2026
5:00 – 6:00 AM Bangkok
Your Medical Notebook: Labs, Meds, Questions, Contacts & Care Info Tracey Silverstein Click Here To Register
UPCOMING SESSIONS in ET
Tue, Jun 2, 2026 · 5:00 – 6:00 AM Bangkok
Your Medical Notebook: Labs, Meds, Questions, Contacts & Care Info
Tracey Silverstein
Click Here To Register
View all sessions

Hereditary Transthyretin Amyloidosis (hATTR) Market Trends, Innovation, and Future Growth Outlook to 2036 - DelveInsight |Alnylam Pharma, Ionis Pharma, Novo Nordisk, AstraZeneca, Pfizer, Intellia

Source
openPR

The Key Hereditary Transthyretin Amyloidosis Companies in the market include - Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Pfizer, Intellia Therapeutics, Regeneron, Neurimmune, Alexion Pharmaceuticals, Novo Nordisk, Eidos Therapeutics, Corino Therapeutics, Prothena, Regeneron Pharmaceutical, and others.

DelveInsight's "Hereditary Transthyretin Amyloidosis Market Insights, Epidemiology, and Market Forecast-2036 report offers an in-depth understanding of the Hereditary Transthyretin Amyloidosis, historical and forecasted epidemiology as well as the Hereditary Transthyretin Amyloidosis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.